A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
Open Access
- 22 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 43 (1) , 1-16
Abstract
Background: Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1) shows a frequent point mutation (E571K) resulting in an altered export of hundreds of cargo proteins, which may impact the success of future therapies in PMBL and cHL. Therefore, targeted therapies have been envisioned for these signaling pathways and mutations. Methods: To identify novel molecular targets that could overcome the treatment resistance that occurs in PMBL and cHL patients, we have explored the efficacy of a first-in-class HSP110 inhibitor (iHSP110-33) alone and in combination with selinexor, a XPO1 specific inhibitor, both in vitro and in vivo. Results: We show that iHSP110-33 decreased the survival of several PMBL and cHL cell lines and the size of tumor xenografts. We demonstrate that HSP110 is a cargo of XPO1wt as well as of XPO1E571K. Using immunoprecipitation, proximity ligation, thermophoresis and kinase assays, we showed that HSP110 directly interacts with STAT6 and favors its phosphorylation. The combination of iHSP110-33 and selinexor induces a synergistic reduction of STAT6 phosphorylation and of lymphoma cell growth in vitro and in vivo. In biopsies from PMBL patients, we show a correlation between HSP110 and STAT6 phosphorylation levels. Conclusions: These findings suggest that HSP110 could be proposed as a novel target in PMBL and cHL therapy.Keywords
Funding Information
- Ligue Contre le Cancer (EL2023 LNCC/CaG)
- Fondation ARC pour la Recherche sur le Cancer
- Institut National Du Cancer (INCa PLBIO20-160, PLBIO21-107, PLBIO22-093)
- Agence Nationale de la Recherche (ANR-11-LABX-0021, ANR-11-LABX-0051, ANR-15-IDE-0003)
This publication has 60 references indexed in Scilit:
- Classical Hodgkin lymphomaThe Lancet, 2021
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trialThe Lancet Haematology, 2020
- Review of precision cancer medicine: Evolution of the treatment paradigmCancer Treatment Reviews, 2020
- Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer2019
- STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphomaCellular Signalling, 2018
- Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasoneCancer Letters, 2016
- Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B‐cell lymphomaAmerican Journal of Hematology, 2016
- Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphomaNature Genetics, 2014
- Targeting heat shock proteins in cancerCancer Letters, 2013
- Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomasLaboratory Investigation, 2009